Gadolinium in dialysis patients.
What's up with that?
#Tweetorial
1/11
Nephrogenic systemic fibrosis (NSF) is an iatrogenic disease that presents with hardening of the skin and other organs. It is often lethal. I treated 5 people with this condition (including one with AKI). Terrible.
2/11
The etiology of NSF was unknown and there were many theories. In 2006, Thomas Grobner published a small case series showing 5 patients developing NSF within weeks of receiving gadolinium contrast for MRI.
3/11pubmed.ncbi.nlm.nih.gov/16431890/
This observation and theory was rapidly replicated and accepted as the cause of NSF. Nephrologists and radiologists stopped giving gadolinium to patients on dialysis and I haven't seen a case since.
4/11
In 2006 the FDA warned physicians and the public about the risk and then in 2007 added black box warnings to gadolinium based contrast agent package labels.
5/11 wayback.archive-it.org/7993/201610222…
But as we looked at the data further it appeared that not all contrast agents had the same toxicity. Gadodiamide (OmniScan) was the agent in 90% of the cases despite having a market share of only 30%.
The American College of Radiology (ACR) breaks down gadolinium based contrast agents (GBCA) into three categories based on the risk of NSF with:
Group 1 being high risk
Group 2 being low risk
Group 3 being unknown
7/11
The obvious recommendation is to choose GBCA from Group 2 and this was backed up by a meta analysis showing that following 4931 administrations of Group 2 GBCA to patients with CKD stage 4, 5 and ESRD, there were ZERO cases of NSF!
8/11 jamanetwork.com/journals/jamai…
For a deep dive into this check out @NephJC's coverage of this meta analysis:
or listen to the @FreelyFiltered podcast on the same manuscript
Gadolinium is removed by dialysis, with approximately 65% removed with a single dialysis session, and the ACR recommends dialyzing people after gad administration but not to initiate dialysis in patients with advanced CKD not on dialysis.
10/11 pubs.rsna.org/doi/full/10.11…
How is gad in ESRD handled at your institution
11/11
I just recently recommended the Renal Physiology book by Bruce Koeppen and Bruce Stanton. I thought it was a good medical student level text book: pbfluids.com/2023/08/ouwb-s…
But I came across this question in Chapter 8 Regulation of Acid Base. It is a straight forward question asking the learner to interpret simple acid-base cases.
But the question falls apart when you look at the answer...
Michael Emmett on electrolyte artifacts
Pre-analytical and analytical #NKFClinicals
Starting with pseudohyponatremia
These are real cases
The osmolality was 294, so there is a huge gap. 44ish
Implies Artifactual decrease in sodium
Her triglycerides were >6000 #NKFClinicals
Note the different between HCO3 and tCO2 should be closer than 19 and 9. #NKFClinicals
I presented a poster at #NKFClinicals. This came from working with ViforCSL on the KALM-1 and KALM-2 meta-analysis of the pivotal trials of difelikefalin for CKD associated pruritus (CKDaP). About a year ago we brainstomed what other lessons could we could pull from the data.
A question we had was how quickly do people respond to the drug, or put more practically, if you start a patient on difelikefalin and a month later they are still having intense itch, how likely will it be that they still could respond?
Look at the only figure on the poster and focus on the bars, this gives the fraction of people who will ultimately respond to difelikefalin who have responded at 4 weeeks, 8 weeks and 12 weeks.